Virus therapy takes on ovarian cancer: new hope in early trial

NCT ID NCT06618235

Recruiting now Disease control Sponsor: Theolytics Limited Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times

Summary

This study tests a new treatment called THEO-260, a virus designed to attack cancer cells, in people with advanced ovarian cancer. About 44 participants will receive different doses to find the safest and most effective one. The goal is to control the disease and reduce tumors, not to cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Centro Integral Oncológico Clara Campal (CIOCC) Hospital
RECRUITING

Madrid, Spain

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Imperial College Healthcare NHS Trust, Hammersmith Hospital
RECRUITING

London, United Kingdom

Contact Phone: •••-•••-•••• Email: •••••@•••••
Oxford University Hospitals NHS Foundation Trust, Churchill Hospital
RECRUITING

Oxford, United Kingdom

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Beatson West of Scotland Cancer Centre
RECRUITING

Glasgow, Scotland, United Kingdom

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

OVARIAN CANCER